Cytokinetics
Coverage of Cytokinetics in the Nexus archive.
- Seaport’s IPO adventure, obesity pill battles, and Makary’s troubles
Seaport Therapeutics CEO Daphne Zohar discusses the company's successful IPO, while notable news includes an obesity pill battle between Eli Lilly and Novo Nordisk, and FDA Commissioner Marty Makary faces White House troubles. This is the 400th episode of a biotech podcast. The episode covers various biotech news including a Phase 3 study win for Cytokinetics.
- STAT+: Are analysts too quick to gloss over Lilly’s liver case?
Vertex Pharma reported first-quarter earnings and shelved an early stage therapy for cystic fibrosis due to poor tolerability. Cytokinetics' drug Myqorzo met efficacy goals in a study of genetic heart disease. Viridian Therapeutics announced positive results from a Phase 3 study of its drug elegrobart.
- STAT+: Cytokinetics drug Myqorzo meets twin efficacy goals in study of genetic heart disease
Cytokinetics' drug Myqorzo met efficacy goals in a Phase 3 clinical trial for non-obstructive hypertrophic cardiomyopathy, a genetic heart disease. The trial's success could expand treatment eligibility and boost peak sales to $5 billion annually. Myqorzo is already in commercial launch for a more severe form of the disease.